Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Inclusion Criteria:

• Patients treated with OAV-101 with a genetically confirmed diagnosis of SMAregardless of the date of diagnosis.

• Appropriate consent/assent has been obtained for participation in the registry

Exclusion Criteria:

• Currently enrolled in an interventional clinical trial involving an investigationalmedicinal product to treat SMA.

Note: Patients who are participating in a Compassionate Use Program (CUP) for OAV-101 (Zolgensma) such as a Managed Access Program (MAP), an Expanded Access Program (EAP), Single Patient Investigational New Drug (IND) (SPI) or Named Patient Program (NPP) are eligible to enroll in the registry regardless of the date of a genetic or clinical diagnosis of SMA.